|
The US Clinical Research Market Outlook to 2017 – Led by Aging Population …
DigitalJournal.com The new drugs such as laquinimod, teriflunomide and dimethyl fumarate, and three mAbs— alemtuzumab, daclizumab and rituximab are anticipated to mask the effects and remit the occurrence of multiple sclerosis” – according to the research report ‘The US … |
|
5 Companies Leading the Fight Against Multiple Sclerosis
Motley Fool Perhaps the most exciting of the bunch, in my opinion as least, is daclizumab, which is being co-developed with AbbVie and is being tested as a relapse-remitting MS therapy that’s injected just once every four weeks. Daclizumab itself is a humanized … |
|
他克莫司缓释胶囊获FDA批准
汉丰网 本报讯 安斯泰来美国子公司近日宣布，其他克莫司缓释胶囊（ASTAGRAF XL）获美国食品药品管理局（FDA）批准，与霉酚酸酯（MMF）及皮质类醇联用、结合或不结合巴利昔单抗（basiliximab），用于预防成人肾移植受者的器官排斥 … |
Biogen Idec Inc (BIIB): Biogen Idec Product Pipeline Will Propel It HigherSeeking AlphaThinking in terms of 2015 and later, by then we should also see [assuming FDA approval] revenue from Daclizumab for MS. Daclizumab is already approved to prevent the…
|
AbbVie Inc. (ABBV) CEO Discusses Q2 2013 Results – Earnings Call Transcript
Seeking Alpha Daclizumab, currently in Phase III development in partnership with Biogen for multiple sclerosis – our second pivotal study will read out next year and we’re planning global registration submissions in 2014 as well. Elagolix is being evaluated in Phase … |
|
New entrants to multiple sclerosis market will drive 10% pa growth through 2018
The Pharma Letter … reformulations of platform injectables and three highly efficacious monoclonal antibodies – Genzyme/Bayer’s (BAYN: DE) Lemtrada (alemtuzumab), Roche (ROG: SIX)/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s (NYSE: ABBV) daclizumab. |
Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call …Seeking AlphaWe continue to make progress with our mid-stage pipeline and expect 3 pivotal readouts over the next 3 years: daclizumab in 2014, TYSABRI and SPMS in 2015 and p…
|
The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As …
Sacramento Bee … be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies— Genzyme/Bayer HealthCare’s Lemtrada, Roche/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s daclizumab. |
|
The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As …
The Providence Journal … be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies– Genzyme/Bayer HealthCare’s Lemtrada, Roche/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s daclizumab. |
|
The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As …
PR Newswire (press release) … be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies— Genzyme/Bayer HealthCare’s Lemtrada, Roche/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s daclizumab. |